At the heart of meeting our patients’ needs and improving their lives is a disciplined, multi-layered approach to research and development (R&D) that truly sets Biogen Idec apart.
We’ve not only revitalized our focus on in-house and collaborative early-stage discovery, but we’re doing it at a time when many major drug companies are pulling back on internal research. In order to spot the best treatment candidates and opportunities, we believe we need to stay ahead of the curve, both scientifically and technologically. This emphasis on breakthrough science is complemented by the scope, relationships and deep talent pool of a global biopharmaceutical company that devotes more than 20 percent of its revenues to developing new therapies.
Our R&D strategy is focused on discovering and developing first-in-class and/or best-in-class molecules that improve the safety or effectiveness of therapies for unmet medical needs. We look for discoveries that either break new ground in treatment or make a meaningful improvement in current therapies.